Arkolith/Insider Trading/TRDA/Form 4

Sethuraman Natarajan

President, Research & Develop.Entrada Therapeutics, Inc. (TRDA) · full profile →Form 4 · filed Mar 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2026Tax withholding(F)8K$11.76$89K242K
Mar 2, 2026Tax withholding(F)4K$11.66$45K250K
Mar 1, 2026Grant(A)56K—$0254K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 1, 2026Grant(A)83K—$083K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001873394-26-000001) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML